In ovarian cancer cells, the overexpression of MLLT11 was also associated with an activation of WNT/beta-catenin/S100A4 oncogenic signals, resulting in malignant tumor progression and metastasis formation and reduced sensitivity to cancer therapy [13]. Here, MLLT11 is linked to ovarian carcinoma.